This preprint is under consideration at BMC Geriatrics. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Artur Cieślewicz
Department of Clinical Pharmacology, Poznan University of Medical Sciences
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background. COVID-19 is an infectious viral disease that has affected more than 234 million people and has caused almost 4.8 million deaths worldwide. A patient's age is the most important factor influencing the risk of severe course of the disease. The elderly usually suffer from many ailments, and therefore, polypharmacy is a common phenomenon among them. Our paper presents the initial results of the analysis of adverse effects in the group of older people in the context of participants' pharmacotherapy.
Methods. The information concerning post-vaccination adverse effects, COVID-19 in the past and current pharmacotherapy was collected from 200 people aged 60 years or older. Statistical analysis was performed using StatSoft Statistica 13.1 software.
Results. Twenty-three participants reported adverse effects after vaccination. Statistical analysis of groups with and without adverse effects revealed significant differences in age, cardiovascular drugs, neurological and psychiatric drugs, analgesics, gastrointestinal drugs, supplements, and vitamins.
Conclusions. Obtained results suggest the need to study the potential effect of ongoing pharmacotherapy on the safety and effectiveness of vaccination.
Keywords
COVID-19 vaccine, safety, the elderly, pharmacotherapy, vaccination, vaccines
Figure 1
No competing interests reported.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 30 Nov, 2021
No community comments so far
Editor invited
On 24 Nov, 2021
Submission checks complete
On 24 Nov, 2021
First submitted
On 02 Nov, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Geriatrics & Gerontology
Learn more about our company.
This preprint is under consideration at BMC Geriatrics. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Artur Cieślewicz
Department of Clinical Pharmacology, Poznan University of Medical Sciences
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 30 Nov, 2021
No community comments so far
Editor invited
On 24 Nov, 2021
Submission checks complete
On 24 Nov, 2021
First submitted
On 02 Nov, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Geriatrics & Gerontology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background. COVID-19 is an infectious viral disease that has affected more than 234 million people and has caused almost 4.8 million deaths worldwide. A patient's age is the most important factor influencing the risk of severe course of the disease. The elderly usually suffer from many ailments, and therefore, polypharmacy is a common phenomenon among them. Our paper presents the initial results of the analysis of adverse effects in the group of older people in the context of participants' pharmacotherapy.
Methods. The information concerning post-vaccination adverse effects, COVID-19 in the past and current pharmacotherapy was collected from 200 people aged 60 years or older. Statistical analysis was performed using StatSoft Statistica 13.1 software.
Results. Twenty-three participants reported adverse effects after vaccination. Statistical analysis of groups with and without adverse effects revealed significant differences in age, cardiovascular drugs, neurological and psychiatric drugs, analgesics, gastrointestinal drugs, supplements, and vitamins.
Conclusions. Obtained results suggest the need to study the potential effect of ongoing pharmacotherapy on the safety and effectiveness of vaccination.
Figure 1
No competing interests reported.
Loading...